Specialty
Aesthetics Cardiology Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Cardiology Interventional Radiology Neurology Optometry Pain Management Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

The State of Geographic Atrophy and Complement System–Based Therapeutics in 2021

By: Charles C. Wykoff, MD, PhD and Jeffrey S. Heier, MD

Webinar Credits: 1.0

The impact on quality of life for patients with geographic atrophy (GA) is significant. Two well-known experts in GA research, Charles C. Wykoff, MD, PHD, and Jeffrey S. Heier, MD, discuss in this webinar the pathogenesis of GA and the complex role of complement system in GA development. In addition, Drs. Wykoff and Heier share the latest clinical trial data for pipeline candidates targeting the complement pathways for the treatment of GA.

This certified CME activity is designed for retina specialists who treat patients with retinal diseases.

Expiration Date: Wednesday, April 06, 2022
Release Date: April 6, 2021

Learning Objectives

At the completion of this educational activity, you will be better able to:

  • Describe the prevalence of advanced age-related macular degeneration (AMD), including advanced AMD (exudative and geographic atrophy [GA]).
  • Explain the pathogenesis of GA.
  • Understand the complex role of complement system in GA development.
  • Outline pipeline candidates targeting the complement pathways that are under investigation for the treatment of GA.

Accreditation and Designation Statement

This educational activity is provided by Evolve Medical Education LLC (Evolve).

Accreditation Statement
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Evolve designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participation Method

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS

Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+

Faculty and Disclosures


Charles C. Wykoff, MD, PhD
Retina Consultants of Texas
Houston Methodist Hospital
Blanton Eye Institute
Houston, Texas

 


Jeffrey S. Heier, MD
Director of the Vitreoretinal Service
Director of Retina Research
Ophthalmic Consultants of Boston
Boston, Massachusetts

 

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.

The following faculty/staff members have the following financial relationships with commercial interests:

Charles C. Wykoff, MD, PhD and or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Adverum, Allergan, Apellis, Arctic Vision, Arrowhead, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong Biotechnologies [KHB], Clearside Biomedical, EyePoint, Genentech, Gyroscope, IVERIC Bio, Kato DSRC, Kodiak Sciences, Merck, NGM Biopharmaceuticals, Novartis, OccuRx, Ocular Therapeutix, ONL Therapeutics, Opthea, Oxurion [formerly Thrombogenics], Palatin, Pentavision, PolyPhotonix, RecensMedical, Regeneron, RegenXBio, Roche, SAI MedPartners, Takeda, Thea Open Innovation, Verana Health; Grant/Research Support: Adverum, Aerie Pharmaceuticals, Aldeyra, Alimera Sciences, Apellis, Bayer, Boehringer Ingelheim, Chengdu Kanghong Biotechnologies (KHB), Clearside Biomedical, Gemini Therapeutics, Genentech, Graybug Vision, Gyroscope, IONIS Pharmaceutical, IVERIC Bio, Kodiak Sciences, LMRI, Neurotech Pharmaceuticals, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, Oxurion, Recens Medical, Regeneron, RegenXBio, Roche, SamChunDang Pharm., Santen, Senju, Taiwan Liposome Company, Xbrane BioPharma

Jeffrey S. Heier, MD, and or spouse/partner has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: 4DMT, Adverum, Aerie, Aerpio, Aldeyra, Allegro, Alzheon, Annexon, Apellis, Aprea, Asclepix, Aviceda, BVT, Dark Horse, DTx, Eloxx, Galimedix, Genentech, Graybug, Gyroscope, Iveric Bio, jCyte, Kanghong, LensGen, NGM, Novartis, Ocular Therapeutix, OcuTerra, Oxurion, Palatin, Regeneron, Regenxbio, Stealth, Thea, Verseon, Vinci, Voyant; Grant/Research Support: Apellis, Asclepix, Bayer, Genentech, Graybug, Gyroscope, Hemera, Iveric Bio, Kanghong, Kodiak, NGM, Notal Vision, Novartis, Regeneron, Regenxbio, Stealth; Stock/Shareholder: Aviceda, Adverum, Allegro, jCyte, Ocular Therapeutix, Vinci

The Evolve staff and planners have no financial relationships with commercial interests.

Nisha Mukherjee, MD, peer reviewer, has no financial relationships with commercial interests.

Disclaimer

OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or IVERIC Bio Inc.

Pretest

  • a. 1b. 2c. 3d. 4e. 5

Video Resources

Next

Test

Instructions

In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.

Step 1 of 2

  • a. 1b. 2c. 3d. 4e. 5
  • AgreeNeutralDisagree
    Describe the prevalence of advanced age-related macular degeneration (AMD), including advanced AMD (exudative and geographic atrophy [GA]).
    Explain the pathogenesis of GA.
    Understand the complex role of complement system in GA development.
    Outline pipeline candidates targeting the complement pathways that are under investigation for the treatment of GA.
Back